DISSEMINATED ON BEHALF OF CONEXEU SCIENCES INC.
CONEXEU SCIENCES Nasdaq: CNXU
↓ Download PDF
AN INVESTOR BRIEFING | MAY 2026

The Billion-Dollar Knock-On Economy
No One Is Talking About

How the GLP-1 super-cycle is opening a new aesthetics super-category, and why Conexeu Sciences Inc. (NASDAQ: CNXU) is engineered for the gap a 30-year-old toolkit cannot fill.

$268.4B
Projected global GLP-1 analogues market by 2030 (from $54.8B in 2024)
BCC Research 3
$97B
Projected global consumer spend on medical aesthetics by 2029 (from $63B in 2024)
Boston Consulting Group 8
~$20.8B
Combined addressable opportunity across the five Conexeu target verticals
Aggregated third-party reports 12

This briefing is intended for informational purposes only. It is not an offer or solicitation to buy or sell securities. Investing in early-stage biomedical companies involves substantial risk, including loss of principal. See the full disclaimer and Forward-Looking Statements on the final page.

01 — THE SET-UP

A Super-Cycle Wall Street Has Already Half-Priced

Investors have been chasing the fountain of youth for sixty years. Some of them have done very well doing it. AbbVie paid roughly $63 billion to acquire Allergan in 2020 — inheriting Botox and Juvederm in the process1. An EQT-led consortium paid approximately CHF 10.2 billion (Swiss francs; roughly US$10.3 billion at completion) in 2019 to carve Galderma and Restylane out of Nestlé Skin Health2.

Now, in our opinion, a new wave is forming behind the largest pharmaceutical adoption curve in a generation: the GLP-1 weight-loss explosion.

BCC Research projects the global GLP-1 analogues market will jump from $54.8 billion in 2024 to $268.4 billion by 2030 — a 30.6% compound annual growth rate3. J.P. Morgan Global Research expects roughly 25 million Americans on GLP-1 treatment by 2030, up from approximately 10 million in 20254. KFF's May 2024 Health Tracking Poll already reported that about 12% of U.S. adults have ever taken a GLP-15.

However, this explosion in GLP-1 usage is setting up a potential economic supercycle that no one is talking about.

“Post-GLP-1 body management is going to emerge as its own category … expanding into regenerative and tissue-health applications as millions of GLP-1 patients seek solutions for laxity rather than volume loss.”
— Dr. Atchima Suwanchinda, MD, MSc, PhD — Vice President, International Society for Dermatologic Surgery 14
02 — THE KNOCK-ON ECONOMY

“Ozempic Face”: A New Patient Cohort That May Outpace the Legacy Aesthetic Toolkit

When tens of millions of people lose 10%, 15%, or more of body weight in a year, faces deflate. Tissue support collapses. Collagen and elastin quality fall. A peer-reviewed systematic review in Aesthetic Surgery Journal Open Forum documents that GLP-1 patients can experience facial volume loss, decreased collagen and elastin, and an advanced-aging appearance — with some patients reportedly appearing up to five years older following significant weight loss6. The authors note that direct causation remains under study, but the clinical picture is real.

McKinsey's late-2024 survey of 174 U.S. medical spas, dermatology, and plastic-surgery providers is, in our view, the cleanest provider-level evidence to date7:

Finding (McKinsey, 2024 provider survey)Share
GLP-1 facial-aesthetic patients with NO prior aesthetic history63%
GLP-1 patients who had never considered aesthetics until weight loss~50%
GLP-1 patients who had lost 11%–30% of body weight61%
GLP-1 patients requesting treatment for multiple concerns at once63%
Providers who said advances in technology are needed to enhance outcomes~33%

Boston Consulting Group, in its 2025 Five Growth Imperatives report, projects that clinical-provider revenue tied specifically to GLP-1 post-weight-loss concerns will grow from approximately $700 million to $2 billion over five years8 — roughly $1.3 billion of incremental clinic revenue that, in our view, will be directed toward tissue-restoration solutions that the current generation of aesthetic products was not designed to address.

03 — MARKET SIZE

A New Aesthetics Super-Cycle

Three independent third-party sources, in our view, point to the same shape: a potentially significant structural increase in spend driven by the convergence of GLP-1 adoption and aesthetic demand.

Category2024 (baseline)ForecastCAGRSource
Global GLP-1 analogues$54.8B$268.4B by 203030.6%BCC Research
Global consumer spend on medical aesthetics$63B~$97B by 2029~9%BCG
Post-GLP-1 provider revenue (U.S. tissue restoration)~$0.7B~$2.0B in five yearsn/mBCG
Adult U.S. GLP-1 ever-users~12% of adults~25M Americans on treatment by 2030n/mKFF / JP Morgan
“The biggest shift we’re seeing, and it’s still accelerating, is the ripple effect of GLP-1 drugs throughout aesthetics. Millions of people are starting or cycling through these medications this year, and the downstream impact is enormous.”
— Dr. Johnny Franco, MD — plastic surgeon, Austin, Texas 15
04 — WHY THE LEGACY TOOLKIT MAY BE INSUFFICIENT

Thirty Years of Packaging. Almost No New Chemistry.

Roughly 90% of dermal-filler procedures globally still rely on hyaluronic acid — the same chemistry that has dominated the field since the late 1990s9. The FDA itself describes the mechanism plainly: HA combines with water in the skin and swells, producing a smoothing or filling effect that typically lasts approximately 6–12 months10.

That is adequate for a forty-year-old seeking to address a wrinkle. For a patient who has lost significant weight on a GLP-1 and is experiencing structural tissue loss, an HA filler adds temporary volume but, in our view, does not address the underlying loss of tissue architecture.

Side-by-side: how today’s products compare

ModalityHow it worksDurationDesigned for tissue restoration?
HA fillers (Restylane, Juvederm)Hyaluronic acid swells with water; adds volume~6–12 monthsNo — temporary space-filler
Biostimulators (Sculptra, Radiesse, Bellafill)Provoke a controlled inflammatory / repair responseMonthsPartial — provoke reaction, no scaffold
Neuromodulators (Botox & Type-A toxins)Temporarily relax muscles by interrupting nerve signaling~3–4 monthsNo — addresses movement, not structure
Surgical fat graftingTransfers autologous fat to deficit sitesVariable / permanentYes — but operating-room procedure
CXU™ device candidateMulti-component collagen-based ECM scaffold (collagen + GAG matrix); ABIOLOGIC; supports endogenous cell migrationInvestigational; designed to support tissue in-growthDesigned as a regenerative scaffold (preclinical; no human clinical data; safety and efficacy not established)
“There will also be a stronger focus on the regenerative side of aesthetics … not just tightening tissue but improving its quality. Technologies and biostimulatory approaches that enhance the extracellular matrix, support lymphatic function, and optimize microcirculation.”
— Dr. Atchima Suwanchinda, MD, MSc, PhD — Vice President, International Society for Dermatologic Surgery 14
05 — INTRODUCING CONEXEU

Conexeu Sciences (NASDAQ: CNXU): Building a new class of regenerative tissue therapies.

Conexeu Sciences Inc. ("Conexeu" or the "Company") is an early-stage medical device company developing CXU™, an injectable bioregenerative extracellular matrix (ECM) scaffold designed to restore soft tissue lost through aging, injury, and GLP-1-associated weight loss.. Conexeu intends to pursue FDA clearance as a Class II device through the 510(k) pathway11.

Per Conexeu materials, the CXU™ device candidate arrives in the syringe as a liquid, rehydrates from a freeze-dried (shelf-stable) form in saline or in the patient’s own plasma, and sets into a soft, gel-like, three-dimensional scaffold at body temperature in approximately ten minutes. The Company refers to this profile as “Ten Minute Tissue.”


https://www.youtube.com/watch?v=UMUkbGQhaCA

What is, and what is not, being claimed

The CXU™ device candidate is…The CXU™ device candidate is NOT…
An ABIOLOGIC deviceA drug, biologic, or growth-factor product
A multi-component collagen-based ECM scaffold (collagen + GAG matrix)A hyaluronic acid filler or biostimulator
Designed to support endogenous cell migration, proliferation, and tissue in-growth through structural and biochemical frameworkDesigned to biologically signal cells
Contains NO growth factors, NO cytokinesReliant on a controlled inflammatory mechanism
In preclinical development; investigational onlyFDA-cleared or commercially available today
“Designing A New Regenerative Platform
  • A single patented formulation, engineered for multi-market scale.
  • An efficient regulatory path to staged, multi-market clearance.
  • One core asset, five potential revenue streams.
  • All rights, title, and interest in the platform IP.
  • 100% owned IP across 40+ countries, anchored by more than a decade of validated preclinical science.
— Conexeu materials
06 — CATEGORY CREATION

Why It’s Different: Creating a New Category, Not Another SKU

In our view, the CXU™ device candidate sits in a sweet spot the legacy stack does not occupy:

Existing categoryWhat it doesWhat it does not do
Temporary HA fillersFill spaceDo not provide a regenerative scaffold
BiostimulatorsProvoke a controlled inflammatory responseDo not provide a scaffold; rely on inflammation
Surgical / fat graftingTransfer tissueRequire an operating room
CXU™ device candidate (investigational)Designed to provide a structural / biochemical framework that supports endogenous cell migration and tissue in-growthDoes NOT biologically signal; not yet FDA-cleared

It is our view that no currently marketed product offers an office-based, injectable scaffold approach with this profile. If preclinical findings translate to clinical performance, Conexeu could, in our opinion, help define a new aesthetics sub-category — though there can be no assurance that preclinical results will be replicated in human clinical trials or that the Company will obtain regulatory clearance.

The key, in our view, is that the CXU™ ECM is designed to provide a scaffold intended to work with the patient's own biology to support tissue regeneration. This mechanism has not yet been validated in human clinical trials.

So instead of filling space, the CXU™ device candidate is designed to support regeneration of tissue lost to rapid weight loss associated with GLP-1 use, aging, or injury. These design goals are based on preclinical findings; clinical significance has not been established.

07 — PLATFORM ECONOMICS

One Platform. Five Verticals. ~$20.8 Billion of Addressable Opportunity.

The CXU™ device candidate is being developed as a platform: a single, patent-protected scaffold formulation that the Company intends to advance across five separately sized vertical markets. This means that one formulation can work within five verticals:

VerticalConexeu thesisEstimated market sizeSource
1. Medical AestheticsTissue restoration for the post-GLP-1 cohort; novel category vs. HA fillers and biostimulators~$11B (aesthetic injectables)Grand View Research
2. Advanced Wound CareLiquid skin substitute that conforms to irregular wound beds; originally invented for burn and warrior care~$2.6B (wound care devices)Market.us
3. Dental Soft Tissue / PeriodontalNext-generation collagen scaffold for guided soft-tissue regeneration in periodontal procedures~$4.2B (referenced range)Company / industry
4. Veterinary Wound CareCollagen-agnostic chemistry extends into companion-animal medicine~$1.4B (animal wound care)MarketResearch.com / VPA
5. 3D Bioprinting Inks & Tissue Scaffoldsa novel 3D-bioprinted breast matrix designed to advance reconstruction beyond implant-based replacement and toward tissue regeneration.Dem onstrated as a printable, medical-grade bioink (Nov 2025 preclinical milestone). ~$1.6BGlobal Market Insights
TOTALSingle patent-protected platform across five on-ramps~$20.8B combinedCompany aggregation of third-party sources
“CXU is building to scale in multiple high-value markets with the potential of additional revenue streams
— Conexeu corporate materials

The ability to apply a single formulation across multiple markets represents, in our view, a range of potential opportunities — though each vertical will require its own regulatory pathway, and there can be no assurance of clearance or commercial success in any of them.

These market sizes are drawn from third-party research and Company materials and are presented for illustrative purposes. They do not represent Conexeu’s revenue, projected revenue, or share of these markets — and Conexeu has no current commercial revenue. See Forward-Looking Statements.

08 — LEADERSHIP

Operators Who Have Built the Last Generation of Aesthetics Franchises

Per Conexeu materials, the management team and advisory bench were assembled with direct experience inside the companies that currently dominate aesthetics:

LeaderRolePrior credentials (per Company materials)
Miles HarrisonPresident, CEO & DirectorFormer President & General Manager, Galderma North America (Aesthetics, Consumer, Prescription); co-founder of Novaestiq Corp.; current board member, Castle Biosciences (NASDAQ: CSTL)
Dr. Brian Pilcher, PhDChief Medical OfficerFormer CMO, Suneva Medical (Bellafill); former VP Medical Affairs, Merz North America (Radiesse) — direct experience with two of the three U.S. biostimulators
Dr. Claudia Chavez-Munoz, MD PhDCo-Founder & Chief Scientific OfficerSurgeon-scientist; Adjunct Professor, Faculty of Medicine, University of British Columbia; scientific architect of the CXU™ scaffold platform
Medical Advisory BoardIndustry KOLsRecognized opinion leaders in plastic surgery, dermatology, wound care, and dentistry; prior advisory relationships with Allergan, Galderma, Merz Aesthetics, Sun Pharma, and Castle Biosciences
“In aesthetics, the operator at the top is the franchise. Allergan and Galderma were not built by people who learned on the job.”
— Editorial view
09 — REASONS TO CONSIDER CONEXEU

Eight Reasons We Believe Conexeu (Nasdaq: CNXU) Belongs on the Watchlist

The following points reflect our editorial view of the opportunity and competitive position, drawn from third-party research and Company materials. They are forward-looking and subject to the risks discussed at the end of this briefing.

1

A macro super-cycle creating structural new demand

GLP-1 adoption is being driven by tens of millions of patients globally. BCC Research projects the global GLP-1 analogues market will reach $268.4 billion by 2030 (30.6% CAGR), and J.P. Morgan expects ~25 million Americans on treatment by 2030. The downstream aesthetic-restoration patient cohort is, in our view, just beginning to arrive in clinics.

2

A documented, third-party-sized unmet clinical need

63% of GLP-1 facial-aesthetic patients have NO prior aesthetic history (McKinsey). BCG projects U.S. provider revenue tied to post-weight-loss concerns will grow from ~$700M to ~$2B in five years. Roughly one in three providers told McKinsey advances in technology are needed.

3

A platform engineered for a category gap, not for incremental improvement

The CXU™ device candidate is an injectable bioregenerative extracellular matrix (ECM) scaffold designed to restore soft tissue lost through aging, injury, and GLP-1-associated weight loss. The CXU™ patented ECM scaffold is designed to supply the three-dimensional framework intended to support tissue regeneration. . It is designed to support endogenous cell migration, proliferation, and tissue in-growth, distinct from the swell-with-water and controlled-inflammation mechanisms of legacy products.

4

A device-first regulatory route that the Company believes is faster and more capital-efficient

Conexeu intends to pursue FDA 510(k) clearance as a Class II device, starting with advanced wound care as a beachhead and then expanding toward the higher-margin aesthetics indication.

5

Five revenue verticals from a single, patent-protected platform

Medical aesthetics (~$11B), advanced wound care (~$2.6B), dental soft tissue (~$4.2B), veterinary wound care (~$1.4B), and 3D bioprinting inks / tissue scaffolds (~$1.6B) — an aggregate ~$20.8B addressable potential opportunity from one core formulation12. These figures represent total market sizes, not the Company's projected revenue or market share.

6

Patent protection across the world's largest aesthetics, wound-care, and dental markets

Per Company materials, granted patents in the United States, the European Union, Japan, and Australia, with a Canadian patent pending. The IP is owned outright, no royalty drag, which the Company believes both protects margin and simplifies any potential strategic transaction.

7

Leadership drawn from the teams behind major aesthetics franchises

A CEO who ran Galderma North America during the company's growth into a global dermatology leader; a CMO with prior senior roles at the makers of two of the three U.S. biostimulators (Bellafill and Radiesse); a co-founder/CSO whose academic career has focused on extracellular-matrix therapies and a medical advisory bench drawn from across Allergan, Galderma, Merz Aesthetics, and Castle Biosciences.

8

A strategic-buyer landscape that has, twice this decade, written ten- and eleven-figure checks for aesthetics franchises

AbbVie acquired Allergan for approximately $63 billion in 2020 (Botox, Juvederm). An EQT-led consortium carved Galderma (Restylane) out of Nestlé Skin Health in a CHF 10.2 billion transaction in 2019. In our view, a small, patent-protected, scaffold-platform company that lands a wound-care 510(k) and produces post-GLP-1 aesthetics data is the kind of asset the next aesthetics transaction has historically looked like.

THE BOTTOM LINE

A Different Idea, Arriving at the Right Moment

Wall Street already understands the GLP-1 obesity-drug story. In our opinion, what Wall Street does not yet fully understand is the second economy forming behind it, and the structural mismatch between a 30-year-old aesthetics chemistry stack and a brand-new, large-volume tissue-restoration need.

Conexeu Sciences (NASDAQ: CNXU) is positioned, in our view, not as another HA filler, not as an obesity-drug story, and not as another small aesthetics start-up, but as an investigational regenerative ECM scaffold platform purpose-built for the gap the legacy toolkit cannot fill, advanced by an operator team that has built category-defining aesthetics franchises before.

“Apple did not invent the smartphone. Tesla did not invent the electric car. They arrived with a different idea, at the right time. We believe Conexeu is arriving at a similar inflection point in aesthetics.”
— Editorial view

As with any early-stage biomedical investment, prospective investors should read Conexeu’s SEC filings on EDGAR, consult a qualified financial advisor, and only risk capital they can afford to lose.

IMPORTANT DISCLOSURES, FORWARD-LOOKING STATEMENTS & SOURCES

Marketing & Compensation Disclosure

[Name of marketing firm] (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Conexeu Sciences Inc. has paid [name of marketing firm] a one-time cash fee of [amount of payment] and/or [number] common shares in consideration for marketing services to be provided over a term of [length of term] commencing [start date]. We or certain non-arm’s-length parties own [number] common shares of Conexeu Sciences Inc. As of the date of this article, we and/or certain non-arm’s-length parties beneficially own [number] common shares of Conexeu Sciences Inc. This article is for informational purposes only. This does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute investment, legal, or tax advice. Prospective investors should consult qualified legal, financial, and tax advisors before making any investment decision. The securities issued by the companies we profile should be considered high risk. If you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. We also recommend reviewing any applicable prospectus or offering memorandum filed by the company. The information contained in this article was obtained from the company directly, as well as from SEDAR+ and SEC filings, company websites, and other publicly available sources. While we believe such information to be accurate and reliable, we cannot guarantee its accuracy and prospective investors should conduct their own due diligence.

Forward-Looking Statements

This article includes certain statements that may be deemed “forward looking statements.” All statements in this article, other than statements of historical facts, that address events or developments that Conexeu Sciences Inc. (the “Company” or “CXU”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward-looking statements include, but are not limited to, statements regarding: the Company’s plans to seek regulatory clearance or approval for its CXU™ product candidates across its target indications, including wound care, dental soft tissue regeneration, veterinary wound care, and medical aesthetics; the Company’s anticipated timelines for regulatory submissions, clinical programs, and commercial market entry across its target verticals; the Company’s belief that its regulatory strategy will compress timelines and reduce costs relative to alternative regulatory pathways; the Company’s expectation that its CXU™ platform is designed to extend across multiple indications from one core formulation; the Company’s expectation regarding the manufacturing, storage, and logistical advantages of its product format, including ambient storage capability, point-of-care reconstitution, and global scalability; the Company’s beliefs, based on preclinical data, regarding the performance characteristics and clinical potential of its CXU™ product candidates; the Company’s expectation regarding its competitive positioning and potential in the medical aesthetics and regenerative medicine markets; and the Company’s estimates regarding the size of the total addressable markets across its target verticals.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others: additional capital requirements; inability to obtain sufficient funding; no history of commercial operations; no operating revenues; global financial conditions; regulatory risks, including the risk that applicable regulatory authorities do not grant clearance or approval for the Company’s product candidates on anticipated timelines or at all; risks related to research and development activities and the uncertainty of their outcomes; manufacturing and supply chain risks; intellectual property risks; commodity markets; insured and uninsured risks; health, safety and community relations; environmental risks and hazards; currency rate risk; infrastructure; competitive industry environment; government regulation; audit of tax filings; management and organizational growth; climate change and climate change regulations; relationship with local communities and other stakeholders; risk of litigation; reliance on key personnel; internal controls; conflicts of interest; interest rate risk; credit risk; liquidity risk; risks related to commercialization of the Company’s products, including market acceptance, pricing, and reimbursement risks; competition from existing and new market entrants; and uninsurable risks.

The forward-looking statements contained herein are made as of the date of this article, and neither the Company nor [name of marketing firm] assumes any obligation to update or revise them to reflect new information, events, or circumstances after the date hereof, except as required by applicable law.

Preclinical Status

The CXU™ device candidate is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical findings; clinical significance has not yet been established. The Company has applied to pursue FDA clearance through the 510(k) pathway as a Class II device. There can be no assurance that the Company will obtain clearance on its anticipated timeline, or at all.

Sources & References

  1. AbbVie completes acquisition of Allergan (approximately $63 billion), 2020. https://pharmatimes.com/news/abbvie_completes_acquisition_of_allergan_1340086/
  2. Galderma carved out of Nestlé Skin Health in CHF 10.2 billion transaction, 2019. https://www.galderma.com/news/galderma-become-worlds-largest-independent-global-dermatology-company-after-completion-chf-102
  3. BCC Research — Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030 (30.6% CAGR; $54.8B in 2024). https://www.bccresearch.com/pressroom/phm/glp-1-analogues-market-to-reach-$2684-billion-by-2030
  4. J.P. Morgan Global Research — Obesity Drugs Outlook (~25 million Americans on GLP-1 by 2030). https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
  5. KFF Health Tracking Poll, May 2024 — The Public's Use and Views of GLP-1 Drugs (~12% of U.S. adults have ever taken a GLP-1). https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/
  6. Aesthetic Surgery Journal Open Forum — systematic review of GLP-1 receptor agonists and facial aging ("Ozempic Face"). DOI: 10.1093/asjof/ojaf056. https://academic.oup.com/asjopenforum/article/doi/10.1093/asjof/ojaf056/8160112
  7. McKinsey & Company (Jansen, Peters, Leclerc) — GLP-1s Are Boosting Demand for Medical Aesthetics, May 15, 2025 (survey of 174 U.S. providers, late 2024). https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
  8. Boston Consulting Group — Five Growth Imperatives for Medical Aesthetics in Times of Uncertainty, 2025 ($63B → ~$97B by 2029; post-GLP-1 provider revenue ~$0.7B → ~$2B). https://media-publications.bcg.com/Five-Growth-Imperatives-for-Medical-Aesthetics-in-Times-of-Uncertainty.pdf
  9. Roots Analysis — Dermal Fillers Market (HA fillers ~90% of global dermal-filler share in 2025). https://www.rootsanalysis.com/reports/dermal-fillers-market.html
  10. U.S. Food and Drug Administration — FDA-Approved Dermal Fillers (HA combines with water and swells; typically lasts ~6–12 months). https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers
  11. Conexeu Sciences, Inc. — Form S-1/A, as filed with the U.S. SEC on March 4, 2026 (EDGAR CIK 0002066836). Class II device; 510(k) pathway; patent assignment from UBC closed April 7, 2025; issued/pending patents in U.S., EU member states, Japan, Australia and Canada (pending). https://www.sec.gov/Archives/edgar/data/2066836/000106299326001297/forms1a.htm
  12. Market sizing for the five Conexeu verticals: Grand View Research (aesthetic injectables ~$11B); Market.us (wound care devices ~$2.6B); Global Market Insights (3D bioprinting ~$1.6B); MarketResearch.com / VPA Research (animal wound care ~$1.4B); dental soft-tissue range per Company materials and industry sources. https://www.grandviewresearch.com/industry-analysis/aesthetic-injectable-market-report
  13. Conexeu Sciences corporate materials (conexeu.com), including press release announcing appointment of Miles Harrison as President and CEO and the Company's Medical Aesthetics technology page. https://conexeu.com
  14. Dr. Atchima Suwanchinda, MD, MSc, PhD — Vice President, International Society for Dermatologic Surgery, quoted in Medical Insight Inc. (MII News), "GLP-1 Pills Disrupt Medspa Industry," Article ID 477. https://miinews.com/Article?id=477
  15. Dr. Johnny Franco, MD — plastic surgeon, Austin, Texas, quoted in Medical Insight Inc. (MII News), "GLP-1 Pills Disrupt Medspa Industry," Article ID 477. https://miinews.com/Article?id=477